Global Medicine Supply Chain Under Strain: Navigating Geopolitical Risks
The ongoing conflict in Iran and escalating tensions surrounding the Strait of Hormuz are introducing latest uncertainties into the global pharmaceutical supply chain. While Spain currently reports no immediate impact on medicine availability, the industry is closely monitoring the situation, recognizing potential mid-term consequences for international logistics.
Rising Transport Costs and Logistical Challenges
A key concern is the increasing strain on transportation and associated costs. Europe’s partial reliance on Asia for active pharmaceutical ingredients (APIs) makes the region particularly vulnerable. The cost of air freight has reportedly increased by up to 400%, adding pressure to a sector already operating with tight margins.
Spain and the EU Intensify Supply Monitoring
The Spanish Agency of Medicines and Medical Products (Aemps) confirms the existence of mechanisms to anticipate potential problems. Laboratories are legally obligated to guarantee supply and notify Aemps of any potential shortfalls, allowing for alternative solutions. Aemps has also “intensified the monitoring of the supply chain” in coordination with industry.
At the European level, the Single Point of Contact (SPOC) Working Group, governed by the Medicines Shortages and Safety Group (MSSG), is closely supervising the impact of the Middle East conflict on medicine supply within the EU. Currently, no critical shortages have been reported, though logistical disruptions are being observed.
Generic Drug Manufacturers Feel the Pressure
The Spanish Association of Generic Medicines (Aeseg) echoes the assessment of stability, but acknowledges growing tension in international logistics. The industry is not currently experiencing direct impacts on manufacturing or short-term supply. However, nearly half of companies are reporting disruptions, particularly along key routes traversing the Middle East.
API Dependence and Stock Levels
A significant worry is the international dependence on APIs, many sourced from Asia. While current stock levels – approximately six months’ supply – are buffering against immediate issues, prolonged disruption could lead to problems. Products requiring cold chains, sterile injectables, and temperature-sensitive items are considered particularly vulnerable.
Diversification as a Key Strategy
Companies like Normon are proactively reinforcing supply chain resilience through diversification. This includes homologating suppliers in Europe, the United States, and Asia to reduce reliance on single sources. Streamlining the API supplier homologation process is also seen as crucial.
Echoes of the Ukraine War: Cost Increases Loom
Farmaindustria warns that a prolonged conflict could mirror the situation following the war in Ukraine, with significant increases in energy costs, raw material prices, and transportation expenses. The impact from the Ukraine war exceeded 900 million euros, without the ability to pass those costs onto consumers.
Pro Tip:
Regularly assess your supply chain for vulnerabilities and develop contingency plans. Diversifying suppliers and maintaining adequate stock levels are essential steps to mitigate risk.
FAQ: Pharmaceutical Supply Chain Disruptions
- Are there medicine shortages in Spain? Currently, no critical shortages have been reported in Spain.
- What is the biggest risk to the supply chain? The increasing cost and disruption of transportation, particularly for APIs sourced from Asia.
- What is being done to address the issue? Increased monitoring by Aemps and the EU, diversification of suppliers, and efforts to streamline homologation processes.
- Will medicine prices increase? The industry warns of potential price increases similar to those seen after the war in Ukraine, but these costs may not be passed on to consumers.
The pharmaceutical sector in Spain demonstrates short-term resilience thanks to existing stocks, diversification efforts, and institutional coordination. However, the evolution of the conflict remains the determining factor. Constant vigilance is essential as the global medicine supply chain navigates this period of heightened uncertainty.
